Мирлокс

Мирлокс – medicine with febrifugal, analgeziruyushchy and antiinflammatory action.

Form of release and structure

Dosage form of release of Mirloks – a tablet: light yellow, round, flat, on one of the parties – dividing risk (on 7,5 mg: on 20 pieces in blisters, 1 blister in a cardboard pack; on 15 mg: on 10 pieces in blisters, 1 or 2 blisters in a cardboard pack).

Is a part of 1 tablet:

• Active ingredient: to meloksika – 7,5 or 15 mg;
• Additional components: the magnesium stearate, lactose micronized кросповидон, corn starch, sodium citrate, maltodextrin.

Indications to use

Мирлокс appoint for a symptomatic treatment of the following diseases:

• Pseudorheumatism;
• Arthrosis;
• Bekhterev's disease (ankylosing spondylarthritis).

Contraindications

Absolute:

• Aggravation of a peptic ulcer of a stomach and duodenum;
• "Aspirinovy" asthma;
• Heavy renal (if the hemodialysis is not carried out) and a liver failure;
• Age up to 15 years;
• Pregnancy and period of breastfeeding;
• Hypersensitivity to drug components.

Relative (Mirloks appoint with respect for care):

• Digestive tract erosive cankers (instructions in the anamnesis);
• Advanced age.

Route of administration and dosage

Pill is taken inside, it is desirable – during food.

The daily dose of Mirloks should be accepted in 1 reception.

Mode of dosing (daily dose):

• Osteoarthrosis: 7,5 mg, are possible increase up to 15 mg;
• Pseudorheumatism: 15 mg, are possible decrease to 7,5 mg;
• Bekhterev's disease: 15 mg.

The maximum dose against the background of a heavy renal failure, existence of risk factors of development of side effects, and also for the patients who are on a hemodialysis makes 7,5 mg a day.

Side effects

• Cardiovascular system: increase in arterial pressure, tachycardia, feeling of inflows;
• Digestive tract: perforation (perforation) of intestines or stomach, a meteorism, nausea, vomiting, increase in activity of liver enzymes, abdominal pains, diarrhea, a lock, digestive tract erosive cankers, gastrointestinal bleedings, dryness in a mouth, hepatitis, stomatitis, colitis, an esophagitis;
• Hemopoietic system: anemia, thrombocytopenia, leukopenia;
• Respiratory system: cough, aggravation of a course of bronchial asthma;
• Urinary system: intersticial nephrite, proteinuria, hypostases, hamaturia, renal medullary necrosis, renal failure, infections of urinary tract;
• Central nervous system: sleep disorder, confusion of thoughts, headache, sonitus, dizziness, disorientation;
• Allergic and dermatological reactions: an allergic vasculitis, an itch, skin rash, the raised photosensitization, a small tortoiseshell, a toxic epidermal necrolysis, anaphylactoid reactions (including an acute anaphylaxis), a paraglossa and lips, a mnogoformny exudative erythema;
• Organ of sight: sight illegibility, conjunctiva inflammation;
• Others: fever.

Special instructions

Care is demanded by Mirloks's appointment in the presence of the following diseases / states:

• Simultaneous use with anticoagulants;
• Peptic ulcer of a stomach and duodenum (anamnestic data).

Also with care and under control of a functional condition of kidneys patients should accept drug at advanced age and to patients with the following diseases / states:

• Chronic heart failure with the circulatory unefficiency phenomena;
• The hypovolemia connected with surgical interventions;
• Cirrhosis.

Correction of the mode of dosing for patients with clearance of creatinine more than 25 ml a minute is not required.

At the combined use with diuretics it is necessary to provide enough liquid.

Development of allergic reactions (in the form of an itch, skin rash, a small tortoiseshell) or a photosensitization can become the therapy cancellation reason.

Because during Mirloks's reception side effects in the form of drowsiness, a headache and dizziness can develop, at control of motor transport and service of mechanisms it is recommended to be careful.

Medicinal interaction

At the combined Mirloks's use with some drugs there can be following effects:

• Intrauterine contraceptives, anti-hypertensive medicines: decrease in their efficiency;
• Diuretics, cyclosporine: increase in probability of development of a renal failure;
• Other non-steroidal anti-inflammatory drugs (including acetylsalicylic acid): increase in risk of development of erosive cankers and bleedings from digestive tract;
• Methotrexate: strengthening of its side effects on the hemopoietic system, increase in danger of development of a leukopenia and anemia (it is recommended to carry out periodically control of the general blood test);
• Lithium drugs: lithium cumulation development, strengthening of its toxic influence (it is recommended to carry out control of concentration to lithium blood);
• Colestyraminum: increase in speed of its removal (because of binding with meloksikamy);
• Trombolitiki (including fibrinolysin, Streptokinasa), anticoagulants (including тиклопидин, heparin, warfarin): increase in probability of development of bleedings (it is recommended to carry out periodically control of blood test on coagulability).

Terms and storage conditions

To store in protected from light, the place, unavailable to children, at a temperature up to 25 °C.

Period of validity – 2 years.